Table 1.
Baseline patient clinical and treatment characteristics
| Baseline characteristics | N | % |
|---|---|---|
| Recruitment site | ||
| Brigham and Women's Hospital | 76/156 | 48.7 |
| Massachusetts General Hospital | 51/156 | 32.7 |
| Beth Israel Deaconess Medical Center | 29/156 | 18.6 |
| Patient age at treatment; median (range), y | 60 (20-92) | |
| Gender, female | 100/156 | 64.1 |
| Karnofsky Performance Status, median (range) | 80 (50-100) | |
| Primary cancer type | ||
| Breast | 33/156 | 21.2 |
| Non-small cell lung carcinoma | 50/156 | 32.1 |
| Melanoma | 35/156 | 22.4 |
| Small cell lung carcinoma | 14/156 | 9.0 |
| Renal cell carcinoma | 9/156 | 5.8 |
| Other | 15/156 | 9.6 |
| Prior radiation to index lesion | ||
| Any | 98/156 | 62.8 |
| WBRT only | 88/156 | 56.4 |
| SRS only | 2/156 | 1.3 |
| WBRT + SRS, focal RT or repeat WBRT | 8/156 | 5.1 |
| Planning target volume; median (range), mL | 3.99 (0.04-58.42) | |
| Index lesion size (maximum axial dimension) | ||
| <2.0 cm | 70/156 | 44.8 |
| 2.0-2.9 cm | 57/156 | 36.5 |
| 3.0-3.9 cm | 21/156 | 13.5 |
| ≥4.0 cm | 6/156 | 3.8 |
| Index lesion location | ||
| Frontal lobe | 47/156 | 30.1 |
| Temporal lobe | 11/156 | 7.1 |
| Parietal lobe | 20/156 | 12.8 |
| Occipital lobe | 9/156 | 5.8 |
| Cerebellum | 37/156 | 23.7 |
| Brainstem | 14/156 | 9.0 |
| Thalamus/basal ganglia | 12/156 | 7.7 |
| Other | 6/156 | 3.8 |
| Total prescription dose; median (range), Gy | 25 (12-36) | |
| Fraction size, median | ||
| ≤3 Gy | 12/156 | 7.7 |
| 4-6 Gy | 104/156 | 66.7 |
| 7-9 Gy | 29/156 | 18.6 |
| ≥10 Gy | 10/156 | 6.4 |
| Number of fractions, median (range) | 5 (2-10) | |
| Number of other brain metastases at treatment | ||
| 0 | 49/156 | 31.4 |
| 1-2 | 54/156 | 34.6 |
| 3-4 | 21/156 | 13.5 |
| ≥5 | 32/156 | 20.5 |
RT, radiation therapy; SRS, stereotactic radiosurgery; WBRT, whole brain radiation therapy.